

Visit 5 – Day 35 (± 3) TeleHealth Visit

Date of Visit: \_\_\_\_/\_\_\_\_/\_\_\_\_ Provide comment if not completed:

Was the visit performed as a telehealth visit due to COVID-19 restrictions?

Yes  No If no, specify reason for telehealth visit

Person contacted for Telehealth Visit:

Patient

Legally Authorized Representative

Note: All information collected per the Telehealth visit is per subject or LAR verbal report.

Inform Patient that a return to clinic visit is required within 30 days to collect safety labs and complete study procedures.

Scheduled Date of Return Visit: \_\_\_\_/\_\_\_\_/\_\_\_\_

**DISCHARGE:**

Has the patient been discharged since Visit 4?  No / previously discharged  Yes

If yes, discharge date: \_\_\_\_/\_\_\_\_/\_\_\_\_ Discharge time: \_\_\_\_\_ am / pm

Facility to which Patient was transferred or discharged:

Home

Nursing facility

Rehab

Hospice facility

Other hospital unit: specify: \_\_\_\_\_

**ANTICOAGULANT THERAPY**

Did patient restart antiplatelet therapy since last visit?

No - reason not restarted:

Not indicated

Continued bleed risk

Pending surgery or other procedure

Other \_\_\_\_\_

Visit 5 – Day 35 (± 3) TeleHealth Visit

<input type="checkbox"/> Yes – record details on Concomitant medication page Name of antiplatelet therapy started: _____
<b>CONCOMITANT MEDICATIONS, ADVERSE EVENTS, INFUSION SITE REACTIONS</b> Any new, or changes, in concomitant medications, Adverse Events or Infusion Site Reactions since last visit? <input type="checkbox"/> No <input type="checkbox"/> Yes* <i>*If yes, complete the applicable worksheet(s)</i>
<b>VITAL STATUS</b> <i>Reminders: Patients who withdraw from the study early should be requested to be contacted for vital status at the end of their planned study period (Day 35).</i>  The status of this patient is: <input type="checkbox"/> Alive <input type="checkbox"/> Deceased* <input type="checkbox"/> Lost to follow-up  *If patient has died, complete an SAE report  Date of death: _____ Cause of death: _____

<b>SIGNATURE SECTION –Source Documents Completed by:</b>		
_____	_____	____/____/____
Printed Name and qualification(s)	Signature	Date

<b>PI SIGNATURE SECTION – Principal Investigator signature is required below to signify review:</b>		
_____	_____	____/____/____
Printed Name	Signature	Date